


Please amend the Claims as follows:

1. (Currently amended) The use of A method of treating attention deficit disorders comprising the step of administering a medicament comprising galantamine or a derivative thereof of formula I:



wherein the broken line represents an optionally present double bond between carbon atoms 3 and 4, each R<sub>1</sub> is independently selected from hydrogen, hydroxyl, straight or branched chain alkyl, hydroxyalkyl, carboxyalkyl amino, alkylamino, acyl, lower alkanoyl, cyano, sulfhydryl, C<sub>1-6</sub> alkoxy, alkylthio, aryloxy, arylthio, R<sub>3</sub>-substituted aryloxy, R<sub>3</sub>-substituted arylthio, aralkoxy, an optionally R<sub>3</sub>-substituted aliphatic or aryl carbamyl group, aralkylthio, R<sub>3</sub>-substituted aralkoxy, R<sub>3</sub>-substituted aralkylthio, aryloxymethyl, R<sub>3</sub>-substituted aryloxymethyl, alkanoyloxy, hydroxy-substituted alkanoyloxy, benzoyloxy, R<sub>3</sub>-substituted benzoyloxy, aryloxycarbonyl and R<sub>3</sub>-substituted aryloxycarbonyl,

R<sub>2</sub> is selected from hydrogen, straight or branched chain C<sub>1-6</sub>alkyl, alkenyl or alkaryl group, optionally substituted by a halogen atom or a cycloalkyl, hydroxy, alkoxy, nitro, amino, aminoalkyl, acylamino, heteroaryl, heteroaryl-alkyl, aryl, arylalkyl, cyano, amyl, aroyl, cycloalkylmethyl, allyl, phenyl, R<sub>3</sub>-substituted phenyl, alkylphenyl, R<sub>3</sub>-substituted alkylphenyl, heterocyclyl selected from α- or β-furyl, α- or β-thienyl, thenyl, pyridyl, pyrazinyl, and pyrimidyl, alkyl-heterocyclyl or

R'-substituted heterocyclyl, where R' is alkyl or alkoxy,

each R<sub>3</sub> is independently selected from hydrogen, hydroxyl, sulfhydryl, alkyl, hydroxyalkyl, aryl, aralkyl, alkoxy, mercaptoalkyl, aryloxy, thiaryloxy, alkaryloxy, mercaptoalkaryl, nitro, amino, N-alkylamino, N-arylamino, N-alkaryl amino, fluoro, chloro, bromo, iodo, and trifluoromethyl,

each R<sub>4</sub> is independently selected from hydrogen, halo, trifluoromethyl or C<sub>1-4</sub>-alkyl,

each R<sub>5</sub> is independently selected from hydrogen or hydroxymethyl,

R<sub>6</sub> is hydrogen or C<sub>1-6</sub>alkyl, ~~or when R<sub>4</sub> at carbon atom 2 is hydroxyl, R<sub>6</sub> may be a moiety of formula I wherein R<sub>6</sub> is hydrogen and R<sub>4</sub> is a linking bond; or~~


R<sub>1</sub> at carbon atom 2 and R<sub>6</sub> may jointly form semicarbazone,

X is oxygen or NR<sub>3</sub>,

Y is nitrogen or phosphorus,

and methylenedioxy derivatives thereof and pharmaceutically acceptable acid addition salts thereof in the manufacture of a medicament for combatting attention deficit disorders, wherein said galantamine derivative is an acetylcholinesterase inhibitor that is active selectively at nicotinic receptor sites and is capable of crossing the blood-brain barrier.

2. (Currently amended) The use of A method of treating attention deficit disorders comprising the step of administering a medicament comprising galantamine or a derivative thereof of formula II



wherein  $R^1$  and  $R^2$  which may be the same or different each represents a hydrogen atom or an acyl group, such as a lower alkanoyl group, e.g. an acetyl group or a straight-chained or branched alkyl group, e.g. methyl, ethyl, propyl, or isopropyl;

$R^3$  is a straight or branched chain alkyl, alkenyl or alkaryl group which is optionally substituted by a halogen atom or a cycloalkyl, hydroxy, alkoxy, nitro, amino, aminoalkyl, acylamino, heteroaryl, heteroarylalkyl, aroyl, aroylalkyl or cyano group; and

$R^4$  represents a hydrogen or a halogen atom attached to at least one of the ring carbons of the tetracyclic skeleton,

and pharmaceutically acceptable salts thereof, such as a hydrobromide, hydrochloride, methylsulphate or methiodide in the manufacture of a medicament for combatting attention deficit disorders, wherein said galantamine derivative is an acetylcholinesterase inhibitor that is active selectively at nicotinic receptor sites and is capable of crossing the blood-brain barrier.

3. (Currently amended) The use of A method of treating attention deficit disorders comprising the step of administering a medicament comprising galantamine or a salt thereof. in the manufacture of a medicament for combating attention deficit disorders

4. (Currently amended) The use is claimed in method of any one of claims 1 to 3, wherein the disorder is attention deficit hyperactivity disorder.

5. (Currently amended) The ~~use as claimed in~~ method of any one of claims 1 to 3, wherein the disorder is a hyperkinetic disorder.

6. Cancelled

7. Cancelled